Drug Trial Radar · NCT07154290
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Mar 18, 2026
Primary completion
Jun 10, 2030
Study completion Jun 10, 2030
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Sep 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate two study drugs called ubamatamab and marlotamig, to see if they can help treat advanced or metastatic Non-Small Cell Lung Cancer (NSCLC), and sarilumab, to evaluate to see if it can help with immune-related side effects from ubamatamab. The study is looking at: * How well ubamatamab and marlotamig work(s) * The side effects that ubamatamab and marlotamig might cause * How much ubamatamab and marlotamig is in the blood at different times * If the body makes antibodies to ubamatamab and/or marlotamig, this may cause the ubamatamab to not work as well
Conditions
- Non Small Cell Lung Cancer
- Advanced Non Small Cell Lung Cancer
- Metastatic Non Small Cell Lung Cancer
- Carcinoma Non Small Cell Lung
Interventions
UbamatamabDrug
Administered per the protocol
MarlotamigDrug
Administered per the protocol
SarilumabDrug
Administered per the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1Time frame: Up to 5 years
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama · Recruiting
Cancer Treatment Centers of America, Phoenix
Goodyear, Arizona · Recruiting
The City of Hope Orange County Lennar Foundation Cancer Center
Irvine, California · Recruiting
ChristianaCare Health System
Newark, Delaware · Recruiting
Georgetown University
Washington D.C., District of Columbia · Recruiting
Mayo Clinic Jacksonville
Jacksonville, Florida · Recruiting
Rush University Medical Center
Chicago, Illinois · Recruiting
University of Illinois Chicago
Chicago, Illinois · Recruiting
Franciscan Health
Munster, Indiana · Recruiting
University of Maryland Greenebaum Comprehensive Cancer Center
Baltimore, Maryland · Recruiting
Mayo Clinic
Rochester, Minnesota · Recruiting
Washington University School of Medicine
St Louis, Missouri · Recruiting
Oregon Health and Science University
Portland, Oregon · Recruiting
University of Tennessee Medical Center
Knoxville, Tennessee · Recruiting
Sarah Cannon Research Institute
Nashville, Tennessee · Recruiting
University of Texas Medical Branch
Galveston, Texas · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
Baylor Scott & White Health
Temple, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.